Stockscreener 앱 받기
26.91
8.29%
2.06
시간 외 거래:
26.99
0.08
+0.30%
전일 마감가:
$24.85
열려 있는:
$25.09
하루 거래량:
3.24M
Relative Volume:
1.81
시가총액:
$2.65B
수익:
$669.43M
순이익/손실:
$-609.36M
주가수익비율:
-4.4071
EPS:
-6.1061
순현금흐름:
$-507.20M
1주 성능:
+17.15%
1개월 성능:
+7.64%
6개월 성능:
-18.97%
1년 성능:
-26.60%
1일 변동 폭
$25.09
$27.90
1주일 범위
$22.48
$27.90
52주 변동 폭
$18.29
$42.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
26.91 | 2.50B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Insider Sell Alert: Sanders Corazon (Corsee) D. Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx EVP sells $46,753 in common stock By Investing.com - Investing.com Australia
Ultragenyx director Corazon D. Sanders sells $50,100 in stock - Investing.com
Ultragenyx EVP sells $46,753 in common stock - Investing.com
Ultragenyx director Corazon D. Sanders sells $50,100 in stock By Investing.com - Investing.com India
Ultragenyx (RARE) director sells 2,000 shares at $25.05 - Stock Titan
Ultragenyx (RARE) legal chief sells 1,899 company shares in open market - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer - Stock Titan
Ultragenyx Pharmaceutical (RARE) Gains 1.5% as Stock Tests Key Resistance Near $25.57Stop Hunt - newsline.com
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks - Insider Monkey
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by GW&K Investment Management LLC - MarketBeat
Motley Fool Wealth Management LLC Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Los Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE: Transformative year ahead with pivotal data, gene therapy launches, and path to profitability - TradingView
RARE: Phase III Angelman data and gene therapy launches set the stage for profitability by 2027 - TradingView
How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE) - Insider Monkey
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com Nigeria
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm - Morningstar
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year - AOL.com
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx CFO Horn sells $110,601 in company stock By Investing.com - Investing.com Australia
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,653 Shares of Stock - MarketBeat
Ultragenyx CFO Horn sells $110,601 in company stock - Investing.com
Ultragenyx Pharmaceutical (RARE) CFO sells 4,653 common shares - Stock Titan
Ultragenyx (RARE) Pushes Higher on Positive Clinical Momentum – Key Levels to WatchNarrow Range Breakout - newsline.com
Ultragenyx (RARE) Shares Slip 1% as Biotech Sector Faces HeadwindsTriple MA Cross - newsline.com
Jefferies Financial Group Inc. Takes $10.97 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Blue Owl Capital Holdings LP Decreases Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Northwestern Mutual Wealth Management Co. Has $4.63 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $72 - Moomoo
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.41 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com - Investing.com South Africa
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $96 - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook - Investing.com
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
울트라제닉스 파마슈티컬 주식 (RARE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Jun 15 '26 |
Sale |
24.62 |
1,899 |
46,753 |
94,462 |
2.60%
0.94%
자본화:
|
볼륨(24시간):